These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 3182416

  • 21. The comparative in-vitro activity of pefloxacin.
    King A, Phillips I.
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():1-10. PubMed ID: 2940213
    [Abstract] [Full Text] [Related]

  • 22. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998.
    Huczko E, Conetta B, Bonner D, Valera L, Stickle T, Macko A, Fung-Tomc J.
    Int J Antimicrob Agents; 2000 Dec; 16(4):401-5. PubMed ID: 11118848
    [Abstract] [Full Text] [Related]

  • 23. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
    Shonekan D, Mildvan D, Handwerger S.
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
    [Abstract] [Full Text] [Related]

  • 24. In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone.
    Neu HC, Chin NX.
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):644-50. PubMed ID: 2506029
    [Abstract] [Full Text] [Related]

  • 25. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
    Wise R, Andrews JM, Brenwald N.
    J Antimicrob Chemother; 1993 Apr; 31(4):497-504. PubMed ID: 8390433
    [Abstract] [Full Text] [Related]

  • 26. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
    Harnett SJ, Fraise AP, Andrews JM, Jevons G, Brenwald NP, Wise R.
    J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
    [Abstract] [Full Text] [Related]

  • 27. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A, Petersen U, Endermann R.
    Chemotherapy; 1996 May; 42(6):410-25. PubMed ID: 8957575
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The in vitro activity of BMS-284756, a new des-fluorinated quinolone.
    Weller TM, Andrews JM, Jevons G, Wise R.
    J Antimicrob Chemother; 2002 Jan; 49(1):177-84. PubMed ID: 11751785
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The comparative in-vitro activity of ofloxacin.
    Grüneberg RN, Felmingham D, O'Hare MD, Robbins MJ, Perry K, Wall RA, Ridgway GL.
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():9-19. PubMed ID: 3182468
    [Abstract] [Full Text] [Related]

  • 36. In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent.
    Cohen MA, Huband MD, Mailloux GB, Yoder SL, Roland GE, Domagala JM, Heifetz CL.
    Antimicrob Agents Chemother; 1991 Jan; 35(1):141-6. PubMed ID: 2014970
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Multicenter Spanish study of ciprofloxacin susceptibility in gram-negative bacteria. The Spanish Study Group on Quinolone Resistance.
    García-Rodríguez JA, Fresnadillo MJ, García MI, García-Sánchez E, García-Sánchez JE, Trujillano I.
    Eur J Clin Microbiol Infect Dis; 1995 May; 14(5):456-9. PubMed ID: 7556239
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.